Article info
Research letter
Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma
- Correspondence to Dr Maria del Carmen Vennera, Department of Pneumology and Respiratory Allergy, Hospital Clinic, Barcelona 08036, Spain; mvennera{at}hotmail.com
Citation
Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma
Publication history
- Received January 18, 2017
- Revised October 6, 2017
- Accepted October 9, 2017
- First published October 27, 2017.
Online issue publication
July 13, 2018
Article Versions
- Previous version (27 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.